The World Trade Center Health Program will now
cover the cost of EsoGuard testing for its more than 120,000
participants
NEW
YORK, Feb. 8, 2024 /PRNewswire/ -- Lucid
Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a
commercial-stage, cancer prevention medical diagnostics company,
and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ)
("PAVmed"), today announced that it has contracted with the World
Trade Center Health Program ("WTCHP") to provide the
EsoGuard® Esophageal DNA test as a covered benefit to
the more than 120,000 responders and survivors who participate in
the program. The WTCHP provides medical monitoring and treatment to
those directly affected by the 9/11 terrorist attacks, including
members of the Fire Department of the City of New York (FDNY) and other emergency
responders at the World Trade Center, recovery and cleanup workers
and those who were in the New York City Disaster Area on
September 11, 2001, or in the months
that followed. EsoGuard is now reimbursable at $2,475.81 per test prescribed by clinicians at
one of WTCHP's Clinical Centers of Excellence.
"We are grateful for the opportunity to provide EsoGuard
esophageal precancer testing to those affected by the devastating
9/11 terrorist attacks," said Lishan
Aklog, M.D., Lucid's Chairman and Chief Executive Officer.
"As a result of their exposure to dust, smoke, and debris, these
heroes are at increased risk of developing cancer, just as
firefighters are in general. In fact, nearly 35,000 have already
been certified as suffering from gastroesophageal reflux disease
(GERD), and therefore are at increased risk of developing
esophageal cancer. Lucid remains deeply committed to expanding
patient access to EsoGuard testing, with the ultimate goal of
preventing esophageal cancer and cancer deaths. We look forward to
offering EsoGuard testing to WTCHP participants through dedicated
#CheckYourFoodTube Precancer Testing events in the New York metropolitan area. This new program
is the product of our ongoing, intensive efforts to drive coverage
for EsoGuard testing through direct contracting initiatives."
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics
company focused on cancer prevention, and subsidiary of PAVmed Inc.
(Nasdaq: PAVM). Lucid is focused on the millions of patients with
gastroesophageal reflux disease (GERD), also known as chronic
heartburn, who are at risk of developing esophageal precancer and
cancer. Lucid's EsoGuard® Esophageal DNA Test, performed
on samples collected in a brief, noninvasive office procedure with
its EsoCheck Esophageal Cell Collection Device, is the first and
only commercially available diagnostic test capable of serving as a
widespread screening tool for at-risk patients to mitigate the
risks of cancer and cancer deaths through early detection of
esophageal precancer.
For more information, please visit www.luciddx.com and for more
information about its parent company PAVmed, please visit
www.pavmed.com.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of Lucid's management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of Lucid's common stock; general economic and market
conditions; the uncertainties inherent in research and development,
including the cost and time required to advance Lucid's products to
regulatory submission; whether regulatory authorities will be
satisfied with the design of and results from Lucid's clinical and
preclinical studies; whether and when Lucid's products are cleared
by regulatory authorities; market acceptance of Lucid's products
once cleared and commercialized; Lucid's ability to raise
additional funding as needed; and other competitive developments.
In addition, Lucid continues to monitor the COVID-19 pandemic and
the pandemic's impact on Lucid's businesses. These factors are
difficult or impossible to predict accurately and many of them are
beyond Lucid's control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a
further list and description of these and other important risks and
uncertainties that may affect Lucid's future operations, see Part
I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission, as the
same may be updated in Part II, Item 1A, "Risk Factors" in any
Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its
most recent Annual Report. Lucid disclaims any intention or
obligation to publicly update or revise any forward-looking
statement to reflect any change in its expectations or in events,
conditions, or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-executes-contract-to-provide-esoguard-esophageal-precancer-testing-as-a-covered-benefit-for-911-responders-and-survivors-302057087.html
SOURCE Lucid Diagnostics